Related references
Note: Only part of the references are listed.A Rat Model of Progressive Nigral Neurodegeneration Induced by the Parkinson's Disease-Associated G2019S Mutation in LRRK2
Julien Dusonchet et al.
JOURNAL OF NEUROSCIENCE (2011)
Preladenant in patients with Parkinson's disease and motor fluctuations: a phase 2, double-blind, randomised trial
Robert A. Hauser et al.
LANCET NEUROLOGY (2011)
Bioactivity of AAV2-Neurturin Gene Therapy (CERE-120): Differences Between Parkinson's Disease and Nonhuman Primate Brains
Raymond T. Bartus et al.
MOVEMENT DISORDERS (2011)
Pathological Gambling in Parkinson Disease Is Reduced by Amantadine
Astrid Thomas et al.
ANNALS OF NEUROLOGY (2010)
Effects of Expectation on Placebo-Induced Dopamine Release in Parkinson Disease
Sarah C. Lidstone et al.
ARCHIVES OF GENERAL PSYCHIATRY (2010)
Impulse Control Disorders in Parkinson Disease A Cross-Sectional Study of 3090 Patients
Daniel Weintraub et al.
ARCHIVES OF NEUROLOGY (2010)
Unilateral pedunculopontine stimulation improves falls in Parkinson's disease
Elena Moro et al.
BRAIN (2010)
Effects of pedunculopontine nucleus area stimulation on gait disorders in Parkinson's disease
M. U. Ferraye et al.
BRAIN (2010)
Relationships between age and late progression of Parkinson's disease: a clinico-pathological study
Peter A. Kempster et al.
BRAIN (2010)
Magnetic resonance imaging markers of Parkinson's disease nigrostriatal signature
Patrice Peran et al.
BRAIN (2010)
In vivo visualization of α-synuclein deposition by carbon-11-labelled 2-[2-(2-dimethylaminothiazol-5-yl)ethenyl]-6-[2-(fluoro)ethoxy]benzoxazole positron emission tomography in multiple system atrophy
Akio Kikuchi et al.
BRAIN (2010)
DJ-1 and α-synuclein in human cerebrospinal fluid as biomarkers of Parkinson's disease
Zhen Hong et al.
BRAIN (2010)
Safinamide in the treatment of Parkinson's disease
Anthony H. V. Schapira
EXPERT OPINION ON PHARMACOTHERAPY (2010)
Current therapeutic targets for the treatment of Alzheimer's disease
Joshua D. Grill et al.
EXPERT REVIEW OF NEUROTHERAPEUTICS (2010)
Pramipexole for the treatment of depressive symptoms in patients with Parkinson's disease: a randomised, double-blind, placebo-controlled trial
Paolo Barone et al.
LANCET NEUROLOGY (2010)
Memantine for patients with Parkinson's disease dementia or dementia with Lewy bodies: a randomised, double-blind, placebo-controlled trial
Murat Emre et al.
LANCET NEUROLOGY (2010)
Gene delivery of AAV2-neurturin for Parkinson's disease: a double-blind, randomised, controlled trial
William J. Marks et al.
LANCET NEUROLOGY (2010)
Minocycline 1-Year Therapy in Multiple-System-Atrophy: Effect on Clinical Symptoms and [11C] (R)-PK11195 PET (MEMSA-Trial)
Richard Dodel et al.
MOVEMENT DISORDERS (2010)
Double-Blind Study of Pardoprunox, a New Partial Dopamine Agonist, in Early Parkinson's Disease
Juliana Bronzova et al.
MOVEMENT DISORDERS (2010)
Task Force Report on Scales to Assess Dyskinesia in Parkinson's Disease: Critique and Recommendations
Carlo Colosimo et al.
MOVEMENT DISORDERS (2010)
Thalamic Single-Unit and Local Field Potential Activity in Tourette Syndrome
Sara Marceglia et al.
MOVEMENT DISORDERS (2010)
Safety and Efficacy of Perampanel in Advanced Parkinson's Disease: A Randomized, Placebo-Controlled Study
Karla Eggert et al.
MOVEMENT DISORDERS (2010)
Enlarged Hyperechogenic Substantia Nigra Is Related to Motor Performance and Olfaction in the Elderly
Daniela Berg et al.
MOVEMENT DISORDERS (2010)
Clinical Efficacy of Istradefylline (KW-6002) in Parkinson's Disease: A Randomized, Controlled Study
Yoshikuni Mizuno et al.
MOVEMENT DISORDERS (2010)
Molecular and clinical prodrome of Parkinson disease: implications for treatment
Anthony H. V. Schapira et al.
NATURE REVIEWS NEUROLOGY (2010)
Diagnostic cerebrospinal fluid biomarkers for Parkinson's disease: A pathogenetically based approach
Karin D. van Dijk et al.
NEUROBIOLOGY OF DISEASE (2010)
Rasagiline, Parkinson neuroprotection, and delayed-start trials Still no satisfaction?
J. Eric Ahlskog et al.
NEUROLOGY (2010)
Depressive symptoms in PD correlate with higher 5-HTT binding in raphe and limbic structures
M. Politis et al.
NEUROLOGY (2010)
Detection of elevated levels of α-synuclein oligomers in CSF from patients with Parkinson disease
T. Tokuda et al.
NEUROLOGY (2010)
Mild cognitive impairment in Parkinson disease A multicenter pooled analysis
D. Aarsland et al.
NEUROLOGY (2010)
CSF amyloid β 1-42 predicts cognitive decline in Parkinson disease
A. Siderowf et al.
NEUROLOGY (2010)
Practice Parameter: Treatment of nonmotor symptoms of Parkinson disease Report of the Quality Standards Subcommittee of the American Academy of Neurology
T. A. Zesiewicz et al.
NEUROLOGY (2010)
Pimavanserin, a Serotonin2A Receptor Inverse Agonist, for the Treatment of Parkinson's Disease Psychosis
Herbert Y. Meltzer et al.
NEUROPSYCHOPHARMACOLOGY (2010)
SNCA Variants Are Associated with Increased Risk for Multiple System Atrophy
Sonja W. Scholz et al.
ANNALS OF NEUROLOGY (2009)
Riluzole treatment, survival and diagnostic criteria in Parkinson plus disorders: The NNIPPS Study
Gilbert Bensimon et al.
BRAIN (2009)
Adenosine and Sleep
Theresa E. Bjorness et al.
CURRENT NEUROPHARMACOLOGY (2009)
Multiple system atrophy: an update
Nadia Stefanova et al.
LANCET NEUROLOGY (2009)
Chronic dopaminergic stimulation in Parkinson's disease: from dyskinesias to impulse control disorders
Valerie Voon et al.
LANCET NEUROLOGY (2009)
Memantine in patients with Parkinson's disease dementia or dementia with Lewy bodies: a double-blind, placebo-controlled, multicentre trial
Dag Aarsland et al.
LANCET NEUROLOGY (2009)
Non-motor symptoms of Parkinson's disease: dopaminergic pathophysiology and treatment
K. Ray Chaudhuri et al.
LANCET NEUROLOGY (2009)
Atomoxetine for the Treatment of Executive Dysfunction in Parkinson's Disease: A Pilot Open-Label Study
Laura Marsh et al.
MOVEMENT DISORDERS (2009)
Neuropsychiatric Symptoms in Parkinson's Disease
Dag Aarsland et al.
MOVEMENT DISORDERS (2009)
Genome-wide association study reveals genetic risk underlying Parkinson's disease
Javier Simon-Sanchez et al.
NATURE GENETICS (2009)
A controlled trial of antidepressants in patients with Parkinson disease and depression
M. Menza et al.
NEUROLOGY (2009)
Disease-modification trials in Parkinson disease: Target populations, endpoints and study design
Olivier Rascol
NEUROLOGY (2009)
High-resolution diffusion tensor imaging in the substantia nigra of de novo Parkinson disease
D. E. Vaillancourt et al.
NEUROLOGY (2009)
A Double-Blind, Delayed-Start Trial of Rasagiline in Parkinson's Disease
C. Warren Olanow et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Multicenter Analysis of Glucocerebrosidase Mutations in Parkinson's Disease
E. Sidransky et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Dopamine Gene Therapy for Parkinson's Disease in a Nonhuman Primate Without Associated Dyskinesia
Bechir Jarraya et al.
SCIENCE TRANSLATIONAL MEDICINE (2009)
Adenosine A2A receptor antagonist istradefylline (KW-6002) reduces Off' time in Parkinson's disease:: A double-blind, randomized, multicenter clinical trial (6002-US-005)
Peter A. LeWitt et al.
ANNALS OF NEUROLOGY (2008)
Caffeine and progression of Parkinson disease
David K. Simon et al.
CLINICAL NEUROPHARMACOLOGY (2008)
A pilot clinical trial of creatine and minocycline in early Parkinson disease: 18-month results
Karl Kieburtz et al.
CLINICAL NEUROPHARMACOLOGY (2008)
Simultaneous Manipulation of Multiple Brain Targets by Green Tea Catechins: A Potential Neuroprotective Strategy for Alzheimer and Parkinson Diseases
Silvia A. Mandel et al.
CNS NEUROSCIENCE & THERAPEUTICS (2008)
Amyloid load in Parkinson's disease dementia and Lewy body dementia measured with [11C]PIB positron emission tomography
P. Edison et al.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2008)
Parkinson's disease: clinical features and diagnosis
J. Jankovic
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2008)
Non-dopaminergic treatments in development for Parkinson's disease
Susan H. Fox et al.
LANCET NEUROLOGY (2008)
LRRK2 Gly2019Ser penetrance in Arab-Berber patients from Tunisia: a case-control genetic study
Mary M. Hulihan et al.
LANCET NEUROLOGY (2008)
Transcranial sonography in movement disorders
Daniela Berg et al.
LANCET NEUROLOGY (2008)
Comparison of desipramine and citalopram treatments for depression in Parkinson's disease:: A double-blind, randomized, placebo-controlled study
David Devos et al.
MOVEMENT DISORDERS (2008)
Study of Istradefylline in Patients with Parkinson's Disease on Levodopa with Motor Fluctuations
Robert A. Hauser et al.
MOVEMENT DISORDERS (2008)
Effects of a NR2B Selective NMDA Glutamate Antagonist, CP-101,606, on Dyskinesia and Parkinsonism
John G. Nutt et al.
MOVEMENT DISORDERS (2008)
The Sydney multicenter study of Parkinson's disease: The inevitability of dementia at 20 years
Mariese A. Hely et al.
MOVEMENT DISORDERS (2008)
A Randomized, Double-Blind, Placebo-Controlled, Delayed Start Study to Assess Rasagiline as a Disease Modifying Therapy in Parkinson's Disease (The ADAGIO Study): Rationale, Design, and Baseline Characteristics
C. Warren Olanow et al.
MOVEMENT DISORDERS (2008)
Efficacy of long-term continuous subcutaneous apomorphine infusion in advanced Parkinson's disease with motor fluctuations: A multicenter study
Pedro J. Garcia Ruiz et al.
MOVEMENT DISORDERS (2008)
Placebo response in Parkinson's disease: Comparisons among 11 trials covering medical and surgical interventions
Christopher G. Goetz et al.
MOVEMENT DISORDERS (2008)
Placebo influences on dyskinesia in Parkinson's disease
Christopher G. Goetz et al.
MOVEMENT DISORDERS (2008)
The Unified Dyskinesia Rating Scale: Presentation and Clinimetric Profile
Christopher G. Goetz et al.
MOVEMENT DISORDERS (2008)
A 12-week, placebo-controlled study (6002-US-006) of istradefylline in Parkinson disease
M. Stacy et al.
NEUROLOGY (2008)
Progression of dopaminergic dysfunction in a LRRK2 kindred A multitracer PET study
R. Nandhagopal et al.
NEUROLOGY (2008)
Second consensus statement on the diagnosis of multiple system atrophy
S. Gilman et al.
NEUROLOGY (2008)
Midbrain iron content in early Parkinson disease - A potential biomarker of disease status
W. R. Wayne Martin et al.
NEUROLOGY (2008)
Measuring health-related quality of life in MSA: The MSA-QoL
Anette Schrag et al.
MOVEMENT DISORDERS (2007)
Clinical diagnostic criteria for dementia associated with Parkinson's disease
Murat Emre et al.
MOVEMENT DISORDERS (2007)
Quantifying the impact of dyskinesias in PD - The PDYS-26: A patient-based outcome measure
R. Katzenschlager et al.
NEUROLOGY (2007)
Levodopa-induced dyskinesias
Giovanni Fabbrini et al.
MOVEMENT DISORDERS (2007)
Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinson's disease: an open label, phase I trial
Michael G. Kaplitt et al.
LANCET (2007)
Safety and tolerability of growth hormone therapy in multiple system atrophy: A double-blind, placebo-controlled study
Bjorn Holmberg et al.
MOVEMENT DISORDERS (2007)
Improvement of gait by chronic, high doses of methylphenidate in patients with advanced Parkinson's disease
D. Devos et al.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2007)
Molecular markers of early Parkinson's disease based on gene expression in blood
Clemens R. Scherzer et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
Sarizotan as a treatment for dyskinesias in Parkinson's disease:: A double-blind placebo-controlled trial
Christopher G. Goetz et al.
MOVEMENT DISORDERS (2007)
Zonisamide improves motor function in Parkinson disease - A randomized, double-blind study
Miho Murata et al.
NEUROLOGY (2007)
Desynchronizing the abnormally synchronized neural activity in the subthalamic nucleus: a modeling study
Christion Hauptmann et al.
EXPERT REVIEW OF MEDICAL DEVICES (2007)
The Parkinson disease gene LRRK2:: Evolutionary and structural insights
Ignacio Marin
MOLECULAR BIOLOGY AND EVOLUTION (2006)
Novel pharmacological targets for the treatment of Parkinson's disease
Anthony H. V. Schapira et al.
NATURE REVIEWS DRUG DISCOVERY (2006)
A randomized trial of deep-brain stimulation for Parkinson's disease
Guenther Deuschl et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Reversible extrapontine and central pontine myelinolysis presenting with extrapyramidal features
B Ho et al.
MOVEMENT DISORDERS (2006)
Randomized controlled trial of intraputamenal glial cell line-derived neurotrophic factor infusion in Parkinson disease
AE Lang et al.
ANNALS OF NEUROLOGY (2006)
Detection of oligomeric forms of α-synuclein protein in human plasma as a potential biomarker for Parkinson's disease
Omar M. A. El-Agnaf et al.
FASEB JOURNAL (2006)
Non-motor symptoms of Parkinson's disease: diagnosis and management
KR Chaudhuri et al.
LANCET NEUROLOGY (2006)
In vivo imaging of microglial activation with [11C](R)-PK11195 PET in idiopathic Parkinson's disease
A Gerhard et al.
NEUROBIOLOGY OF DISEASE (2006)
Diagnosis and management of dementia with Lewy bodies - Third report of the DLB consortium
IG McKeith et al.
NEUROLOGY (2005)
Effects of dyskinesias in Parkinson's disease on quality of life and health-related costs:: a prospective European study
M Péchevis et al.
EUROPEAN JOURNAL OF NEUROLOGY (2005)
Loss of function mutations in the gene encoding Omi/HtrA2 in Parkinson's disease
KM Strauss et al.
HUMAN MOLECULAR GENETICS (2005)
FDG PET in the differential diagnosis of parkinsonian disorders
T Eckert et al.
NEUROIMAGE (2005)
Depression in Parkinson's disease: loss of dopamine and noradrenaline innervation in the limbic system
P Remy et al.
BRAIN (2005)
Evidence-based medical review update: Pharmacological and surgical treatments of Parkinson's disease: 2001 to 2004
CG Goetz et al.
MOVEMENT DISORDERS (2005)
Nigrostriatal dopaminergic deficits and hypokinesia caused by inactivation of the familial Parkinsonism-linked gene DJ-1
MS Goldberg et al.
NEURON (2005)
Sydney multicenter study of Parkinson's disease: non-L-dopa-responsive problems dominate at 15 years
MA Hely et al.
MOVEMENT DISORDERS (2005)
Duodenal levodopa infusion monotherapy vs oral polypharmacy in advanced Parkinson disease
D Nyholm et al.
NEUROLOGY (2005)
The role of radiotracer imaging in Parkinson disease
B Ravina et al.
NEUROLOGY (2005)
Animal models of multiple system atrophy
N Stefanova et al.
TRENDS IN NEUROSCIENCES (2005)
Combination of 'idiopathic' REM sleep behaviour disorder and olfactory dysfunction as possible indicator for alpha-synucleinopathy demonstrated by dopamine transporter FP-CIT-SPECT
K Stiasny-Kolster et al.
BRAIN (2005)
The new mutation, E46K, of α-synuclein causes Parkinson and Lewy body dementia
JJ Zarranz et al.
ANNALS OF NEUROLOGY (2004)
α-synuclein locus duplication as a cause of familial Parkinson's disease
MC Chartier-Harlin et al.
LANCET (2004)
Rivastigmine for dementia associated with Parkinson's disease
M Emre et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Development and validation of the Unified Multiple System Atrophy Rating Scale (UMSARS)
GK Wenning et al.
MOVEMENT DISORDERS (2004)
Mutations in LRRK2 cause autosomal-dominant Parkinsonism with pleomorphic pathology
A Zimprich et al.
NEURON (2004)
Clozapine in drug induced psychosis in Parkinson's disease:: a randomised, placebo controlled study with open follow up
P Pollak et al.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2004)
Five-year follow-up of bilateral stimulation of the subthalamic nucleus in advanced Parkinson's disease
P Krack et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
α-synuclein locus triplication causes Parkinson's disease
AB Singleton et al.
SCIENCE (2003)
Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL-PET study
AL Whone et al.
ANNALS OF NEUROLOGY (2003)
Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease
SS Gill et al.
NATURE MEDICINE (2003)
Memantine in moderate-to-severe Alzheimer's disease
B Reisberg et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Caffeine, postmenopausal estrogen, and risk of Parkinson's disease
A Ascherio et al.
NEUROLOGY (2003)
Nigrostriatal α-synucleinopathy induced by viral vector-mediated overexpression of human α-synuclein:: A new primate model of Parkinson's disease
D Kirik et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
How valid is dopamine transporter imaging as a surrogate marker in research trials in Parkinson's disease?
PK Morrish
MOVEMENT DISORDERS (2003)
Quantitative description of loss of clinical benefit following withdrawal of levodopa-carbidopa and bromocriptine in early Parkinson's disease
RA Hauser et al.
MOVEMENT DISORDERS (2002)
α-Synucleinopathy and selective dopaminergic neuron loss in a rat lentiviral-based model of Parkinson's disease
C Lo Bianco et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2002)
Localization of a novel locus for autosomal recessive early-onset parkinsonism, PARK6, on human chromosome 1p35-p36
EM Valente et al.
AMERICAN JOURNAL OF HUMAN GENETICS (2001)
Pramipexole vs levodopa as initial treatment for Parkinson disease - A randomized controlled trial
R Holloway et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2000)
Dopaminergic loss and inclusion body formation in α-synuclein mice:: Implications for neurodegenerative disorders
E Masliah et al.
SCIENCE (2000)
Forty-five years of stereotactic surgery for Parkinson's disease: A review
J Gillingham
STEREOTACTIC AND FUNCTIONAL NEUROSURGERY (2000)
Share Paper
